Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Product information and disease descriptionProduct description

Phase of product development

24 evidence topics · 21 sources

Regulatory status: Under review; NDA accepted July 2026, PDUFA target action date April 2027
Development history: RAPIDe-3 initiation, enrollment, and topline results
FDA clinical hold, August 2022, and its lifts in June 2023 and January 2024
EU paediatric investigation plan, agreed October 2023 and modified January 2025
FDA expedited program designations

No evidence found.